Carney can fight now, or he should surrender

In the latest episode of The Line Podcast, recorded on August 14th, 2026, Matt Gurney and Jen Gerson begin with a lengthy discussion of the state of the Canada–U.S. trade war. 

This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com

Your hosts are in complete agreement: Canada should not accept a bad deal. A bad deal wouldn't buy lasting peace, they argue — it would simply set the stage for the next round of American demands. In their view, there is no stable middle ground. Canada either resists now or surrenders now. They also examine the unusual political psychology of the Americans currently running the White House, while cautioning listeners not to expect salvation from the Democrats. A future Democratic administration may be less abrasive, but it won't undo the underlying shift in American policy. As Matt puts it, quoting the late Chris Cornell, "Arm yourselves because no one else here will save you." That includes the likes of Gavin Newsom and Chuck Schumer.

This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.

Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.

Find them Fractional-Execs.ca.

From there, the hosts turn to Alberta and a fascinating Toronto Star investigation tracking the flow of money supporting the separatist movement. The reporting closely matches what both Line editors had already concluded independently. Jen offers an update from the ground in Alberta, while Matt steps back to consider the national implications. Both arrive at the same frustrating conclusion: it would be helpful if Canada's institutions were capable of recognizing foreign interference when it was happening. Recent history suggests we're not only bad at it — we don't even seem particularly interested in trying.

Finally, Matt and Jen close with a friendly disagreement over the controversy surrounding Prime Minister Mark Carney's vacation in Italy. They don't see eye to eye, and by the end of the conversation it's clear Matt is unlikely to invite Jen along on his next European vacation. If you'd like to help fund that hypothetical trip, your hosts suggest the usual: like, subscribe, and donate generously.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit. This summer, BioCanRx and The Line have been talking about potential solutions for the problems that are limiting Canada’s ability to domestically develop new drugs, especially immunotherapies for cancer.

We ask a lot of Canadian cancer researchers. The work required to discover new therapies for numerous diseases, and get them to patients, costs far more than the half-billion dollars invested in cancer research by all levels of government and charities — and often the available grants specialize in only one part of the spectrum: discovery. We need to be sure we’re supporting researchers at every step of this complex scientific and regulatory process.

BioCanRx has proved you can meaningfully support this part. The entire team is only 12 people, but they know what it takes to do things like submit a clinical trial application or safely manufacture a drug, so the researchers they fund are held to firm, realistic standards that make sense in the real world of Canadian health-care systems and industry. That’s how a tiny not-for-profit has helped bring 16 new drugs to clinical trials that have treated more than 400 people in just 10 years.

But research is only one part of the puzzle — can we manufacture new therapies in Canada? More on that next time.

Visit BioCanRx.com to learn more.

All that and more in the latest episode of The Line Podcast.

#TheLinePodcast
#MarkCarney
#CanadaUSRelations
#TradeWar
#CanadianPolitics
#AlbertaPolitics
#ForeignInterference
#GavinNewsom
#ChuckSchumer
#CurrentAffairs